Special Issue

Smooth Muscle and Endothelial Cells as Pharmacological Targets for Acute Oxidative Stress

Message from the Guest Editor

Reactive oxygen species (ROS) play an important role in physiological cell signaling. However, excessive levels of ROS damage cells. Acute oxidative stress results from ischemia reperfusion injuries such as stroke, myocardial infarction, and vascular occlusion during surgery in addition to acute injuries such as traumatic brain injury. While great attention has been devoted to limiting damage from acute oxidative stress on the surrounding tissue, the development of strategies to limit smooth muscle and endothelial cell damage to maintain perfusion to the effected tissue is emerging as a promising therapeutic focus. Damage to smooth muscle and endothelial cells can impair vasomotor control and result in cell death. Recent efforts have begun to evaluate how to ameliorate this damage. In this Special Issue, we seek to bring together research from experts in the field to highlight pharmacological targets to limit vascular cell damage in response to acute oxidative stress. I look forward to receiving your valuable contributions.

Guest Editor

Dr. Charles E. Norton

Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65212, USA

Deadline for manuscript submissions

closed (25 November 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 6.1 Indexed in PubMed



mdpi.com/si/184352

Pharmaceuticals
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)

